雷尼替丁 (Chinese Wikipedia)

Tang AW. A practical guide to anaphylaxis. American Family Physician. October 2003, 68 (7): 1325–1332 [2017-02-03]. PMID 14567487. （原始内容存档于2017-01-10）.

aapsus.org (Global: low place; Chinese: low place)

Anaphylaxis: Diagnosis and Management in the Rural Emergency Department (PDF). American Journal of Clinical Medicine. [2017-02-03]. （原始内容存档 (PDF)于2016-08-14）.

adsabs.harvard.edu (Global: 14^th place; Chinese: 27^th place)

ui.adsabs.harvard.edu

Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, Alghamdi M, Khan AR, Erwin PJ, Sutton AJ, Baddour LM. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLOS ONE //www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620 |PMC=缺少标题 (帮助). 2013, 8 (3). Bibcode:2013PLoSO...856498T. PMC 3587620 . PMID 23469173. doi:10.1371/journal.pone.0056498 . 已忽略未知参数|article-number= (帮助)

archive.org (Global: 6^th place; Chinese: 2^nd place)

Force RW, Nahata MC. Effect of histamine H2-receptor antagonists on vitamin B12 absorption. The Annals of Pharmacotherapy. October 1992, 26 (10): 1283–1286. PMID 1358279. S2CID 35308626. doi:10.1177/106002809202601018.
Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. Journal of Clinical Epidemiology. May 2001, 54 (5): 531–534. PMID 11337218. doi:10.1016/S0895-4356(00)00340-1.
Cobelens FG, Leentvaar-Kuijpers A, Kleijnen J, Coutinho RA. Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. Tropical Medicine & International Health. November 1998, 3 (11): 896–903. PMID 9855403.
Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. March 1980, 1 (8170): 672–674. PMID 6103090. S2CID 35753958. doi:10.1016/s0140-6736(80)92826-3.
Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB Journal. April 2005, 19 (6): 656–658. PMID 15671152. S2CID 18832411. doi:10.1096/fj.04-3170fje .
Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. August 2010, 67 (16): 1344–1350. PMID 20689123. S2CID 12339028. doi:10.2146/ajhp090477.

bfarm.de (Global: low place; Chinese: low place)

Ranitidine - core safety profile (PDF). Bundesinstitut für Arzneimittel und MedizinProdukte. [2019-09-29]. （原始内容存档 (PDF)于2020-11-26）.

biopharmadive.com (Global: low place; Chinese: low place)

CVS suspends Zantac sales, as recalls widen over carcinogen fears. BioPharma Dive. 2019-09-30 [2019-10-18]. （原始内容存档于2019-10-19）.

bloomberg.com (Global: 118^th place; Chinese: 182^nd place)

Zantac's Maker Kept Quiet About Cancer Risks for 40 Years. Bloomberg. 2023-02-15 [2023-02-20]. （原始内容存档于2023-02-19）.

books.google.com (Global: 3^rd place; Chinese: 6^th place)

Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 444. ISBN 978-3-527-60749-5. （原始内容存档于2016 -12-20）.

canada.ca (Global: 1,114^th place; Chinese: 1,607^th place)

canada.ca

Nitrosamine impurities in medications: Medications affected. Health Canada. 2021-03-19 [2024-01-07].

recalls-rappels.canada.ca

Acid Reducer (Ranitidine) Tablet: N-nitrosodimethylamine (NDMA) impurity. Health Canada. 2021-12-06 [2024-01-07]. （原始内容存档于2025-03-16）.

clincalc.com (Global: 5,833^rd place; Chinese: 2,124^th place)

Ranitidine - Drug Usage Statistics. ClinCalc. [2024-03-25]. （原始内容存档于2021-12-07）.

doi.org (Global: 2^nd place; Chinese: 5^th place)

Gardner JD, Ciociola AA, Robinson M, McIsaac RL. Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity. Alimentary Pharmacology & Therapeutics. July 2002, 16 (7): 1317–1326. PMID 12144582. S2CID 34396030. doi:10.1046/j.1365-2036.2002.01291.x .
Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM. Is this the end for ranitidine? NDMA presence continues to confound. Clinical and Translational Science. July 2021, 14 (4): 1197–1200. PMC 8301580 . PMID 33934515. doi:10.1111/cts.12995.
Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, Alghamdi M, Khan AR, Erwin PJ, Sutton AJ, Baddour LM. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLOS ONE //www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620 |PMC=缺少标题 (帮助). 2013, 8 (3). Bibcode:2013PLoSO...856498T. PMC 3587620 . PMID 23469173. doi:10.1371/journal.pone.0056498 . 已忽略未知参数|article-number= (帮助)
World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474 . hdl:10665/382243 . License: CC BY-NC-SA 3.0 IGO.
Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia. June 2009, 64 (6): 652–657. PMID 19453319. S2CID 7799380. doi:10.1111/j.1365-2044.2008.05861.x .
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Medicine. February 2013, 39 (2): 165–228. PMC 2249616 . PMID 23361625. doi:10.1007/s00134-012-2769-8.
Force RW, Nahata MC. Effect of histamine H2-receptor antagonists on vitamin B12 absorption. The Annals of Pharmacotherapy. October 1992, 26 (10): 1283–1286. PMID 1358279. S2CID 35308626. doi:10.1177/106002809202601018.
Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. Journal of Clinical Epidemiology. May 2001, 54 (5): 531–534. PMID 11337218. doi:10.1016/S0895-4356(00)00340-1.
Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. January 1994, 308 (6922): 176. PMC 2542523 . PMID 7906170. doi:10.1136/bmj.308.6922.176.
Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ. February 1996, 312 (7028): 414–415. PMC 2350063 . PMID 8601113. doi:10.1136/bmj.312.7028.414.
Wickramasinghe LS, Basu SK. Salmonellosis during treatment with ranitidine. Unreviewed reports. BMJ. 1984, 289 (6454): 1272. doi:10.1136/bmj.289.6454.1272 .
Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. March 1980, 1 (8170): 672–674. PMID 6103090. S2CID 35753958. doi:10.1016/s0140-6736(80)92826-3.
Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB Journal. April 2005, 19 (6): 656–658. PMID 15671152. S2CID 18832411. doi:10.1096/fj.04-3170fje .
Mallow S, Rebuck JA, Osler T, Ahern J, Healey MA, Rogers FB. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?. Current Surgery. 2004, 61 (5): 452–458. PMID 15475094. doi:10.1016/j.cursur.2004.03.014.
Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. May 2006, 117 (5): e817–e820. PMID 16651285. S2CID 23719299. doi:10.1542/peds.2005-1655.
Bangia AV, Kamath N, Mohan V. Ranitidine-induced thrombocytopenia: A rare drug reaction. Indian Journal of Pharmacology //www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128 |PMC=缺少标题 (帮助). February 2011, 43 (1): 76–77. PMC 3062128 . PMID 21455428. doi:10.4103/0253-7613.75676 .
Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, Phelps DL. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. February 2006, 117 (2): e137–e142. PMID 16390920. S2CID 41491264. doi:10.1542/peds.2005-1543.
Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Canani RB. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. January 2012, 129 (1): e40–e45. PMID 22157140. doi:10.1542/peds.2011-0796 .
Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. August 2010, 67 (16): 1344–1350. PMID 20689123. S2CID 12339028. doi:10.2146/ajhp090477.
Wang CH, Chen II, Chen CH, Tseng YT. Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study. International Journal of Environmental Research and Public Health //www.ncbi.nlm.nih.gov/pmc/articles/PMC9566239 |PMC=缺少标题 (帮助). September 2022, 19 (19). PMC 9566239 . PMID 36231768. doi:10.3390/ijerph191912469 . 已忽略未知参数|article-number= (帮助)
Roberts CJ. Clinical pharmacokinetics of ranitidine. Clinical Pharmacokinetics. 1984, 9 (3): 211–221. PMID 6329583. S2CID 21561498. doi:10.2165/00003088-198409030-00003.
Li JJ. Beginning of an Era: The First Blockbuster Drug, Tagamet. academic.oup.com. 2014 [2024 -10-22]. ISBN 978-0-19-973768-0. doi:10.1093/oso/9780199737680.003.0005.
Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. The New England Journal of Medicine. March 1998, 338 (11): 719–726. PMID 9494148. doi:10.1056/NEJM199803123381104 .

drugs.com (Global: 529^th place; Chinese: 229^th place)

Ranitidine use during pregnancy. Drugs.com. 2019-12-02 [2019-12-13]. （原始内容存档于2019-10-29）.
Ranitidine hydrochloride monograph. The American Society of Health-System Pharmacists. [2015-12-01]. （原始内容存档于2017-09-09）.

espacenet.com (Global: 950^th place; Chinese: 938^th place)

worldwide.espacenet.com

US patent 4128658,「Aminoalkyl furan derivatives」

europa.eu (Global: 62^nd place; Chinese: 150^th place)

ema.europa.eu

Ranitidine-containing medicinal products. European Medicines Agency (EMA). 2020-04-30 [2020-05-06]. （原始内容存档于2020-05-06）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
EMA to provide guidance on avoiding nitrosamines in human medicines. European Medicines Agency (EMA) (新闻稿). 2019-09-13 [2019-09-19]. （原始内容存档于2019-12-31）.
Suspension of ranitidine medicines in the EU. European Medicines Agency (EMA) (新闻稿). 2020-04-30 [2020-06-02]. （原始内容存档于2021-01-05）.
EMA. Suspension of ranitidine medicines in the EU. European Medicines Agency (EMA). 2020-04-30 [2023-03-27]. （原始内容存档于2021-01-05）.
Nitrosamine impurities. European Medicines Agency (EMA). 2020-08-06 [2020-08-06]. （原始内容存档于2020-08-04）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020. European Medicines Agency (EMA) (新闻稿). 2020-04-30 [2020-05-06]. （原始内容存档于2020-05-07）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov (Global: 470^th place; Chinese: 386^th place)

fda.gov

Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. U.S. Food and Drug Administration (FDA) (新闻稿). 2019-09-13 [2019-09-26]. （原始内容存档于2019-09-26）. 本条目含有公有领域來源内容。
FDA updates and press announcements on NDMA in Zantac (ranitidine). U.S. Food and Drug Administration (FDA) (新闻稿). 2019-10-28 [2019-10-28]. （原始内容存档于2019-10-29）. FDA observed the testing method used by a third-party laboratory uses higher temperatures. The higher temperatures generated very high levels of NDMA from ranitidine products because of the test procedure. The FDA published the method for testing angiotensin II receptor blockers (ARBs) for nitrosamine impurities. That method is not suitable for testing ranitidine because heating the sample generates NDMA.
FDA recommends using an LC-HRMS testing protocol to test samples of ranitidine. FDA's LC-HRMS testing method does not use elevated temperatures and has shown the presence of much lower levels of NDMA in ranitidine medicines than reported by the third-party laboratory. International regulators using similar LC-MS testing methods have also shown the presence of low levels of NDMA in ranitidine samples. 本条目含有公有领域來源内容。
Questions and Answers: NDMA impurities in ranitidine (commonly known as Zantac). U.S. Food and Drug Administration (FDA). 2019-10-11 [2019-10-23]. （原始内容存档于2019-10-24）. 本条目含有公有领域來源内容。
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. U.S. Food and Drug Administration (FDA) (新闻稿). 2020-04-01 [2020-04-01]. （原始内容存档于2021-03-28）. 本条目含有公有领域來源内容。
FDA Approves Reformulated Ranitidine Following Comprehensive Safety Review. U.S. Food and Drug Administration (FDA). 2025-11-25 [2025-11-26]. （原始内容存档于2025-12-31）.
Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines. U.S. Food and Drug Administration (FDA). 2019-09-12 [2020-05-06]. （原始内容存档于2020-05-06）.
Statement on new testing results, including low levels of impurities in ranitidine drugs. U.S. Food and Drug Administration (FDA) (新闻稿). 2019-11-01 [2019-11-01]. （原始内容存档于2019-11-02）. 本条目含有公有领域來源内容。
Laboratory tests - Ranitidine. U.S. Food and Drug Administration (FDA). 2019-11-01 [2019-11-01]. （原始内容存档于2019-11-02）. 本条目含有公有领域來源内容。
FDA Provides Guidance to Industry for Detecting and Preventing Nitrosamines in Drugs. U.S. Food and Drug Administration (FDA) (新闻稿). 2020-09-014 [2020-09-01]. （原始内容存档于2020-09-01）. 请检查|date=中的日期值 (帮助)
Control of Nitrosamine Impurities in Human Drugs. U.S. Food and Drug Administration. 2021-02-24 [2024-09-06]. （原始内容存档于2020-09-01）.
Apotex Corp. issues voluntary nationwide recall of Ranitidine tablets 75mg and 150mg (all pack sizes and formats) due to the potential for detection of an amount of unexpected impurity, N-nitrosodimethylamine (NDMA) impurity in the product. U.S. Food and Drug Administration (FDA). 2019-09-26 [2019-09-26]. （原始内容存档于2019-09-26）. 本条目含有公有领域來源内容。
Perrigo Company plc issues voluntary worldwide recall of Ranitidine due to possible presence of impurity, N-nitrosodimethylamine (NDMA) impurity in the product. U.S. Food and Drug Administration (FDA). 2019-10-23 [2019-10-23]. （原始内容存档于2019-10-24）. 本条目含有公有领域來源内容。

accessdata.fda.gov

Zantac. U.S. Food and Drug Administration (FDA). [2019-10-18]. NDA 021698. （原始内容存档于2019-10-30）. 本条目含有公有领域來源内容。

gskpro.com (Global: low place; Chinese: low place)

Zantac recall – UK recall of Zantac (Ranitidine API), incl. Zantac Injection, Zantac Tablets, Zantac Syrup. GlaxoSmithKline. October 2019 [2020-03-30]. （原始内容存档于2021-12-11）.

hdl.handle.net (Global: 66^th place; Chinese: 243^rd place)

World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474 . hdl:10665/382243 . License: CC BY-NC-SA 3.0 IGO.

healthycanadians.gc.ca (Global: low place; Chinese: low place)

Health Canada assessing NDMA in ranitidine. Health Canada. 2019-09-13 [2019-09-26]. （原始内容存档于2019-09-26）.
Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; additional products being recalled - Recalls and safety alerts. Health Canada. 2019-09-26 [2019-09-26]. （原始内容存档于2019-09-26）.

hres.ca (Global: low place; Chinese: 7,116^th place)

pdf.hres.ca

Product monograph - PrAcid reducer (PDF). （原始内容 (PDF)存档于2024-01-07）.

lexi.com (Global: low place; Chinese: low place)

online.lexi.com

Ranitidine drug information. Lexicomp. （原始内容存档于2014-04-20）.

medicaldialogues.in (Global: low place; Chinese: low place)

Rantac OD 300. Medical Dialogues. [2021-01-19]. （原始内容存档于2022-07-04）.

mhprofessional.com (Global: low place; Chinese: low place)

Brunton L, Lazo J, Parker K. Goodman & Gilman's The Pharmacological Basis of Therapeutics 11. McGraw-Hill. August 2005: 972. ISBN 978-0-07-142280-2. （原始内容存档于2016-04-11）.

mhra.gov.uk (Global: low place; Chinese: low place)

cas.mhra.gov.uk

MHRA Central Alerting System – Ranitidine: all oral formulations. Supply disruption.. CAS.MHRA.GOV.uk. Medicines and Healthcare products Regulatory Agency (MHRA). 2019-10-15 [2020-03-30]. （原始内容存档于2020-08-13）. All oral formulations of ranitidine are shortly anticipated to be out of stock until further notice. This alert provides healthcare professionals with advice on the management of patients currently taking ranitidine.

nih.gov (Global: 5^th place; Chinese: 3^rd place)

ncbi.nlm.nih.gov

Gardner JD, Ciociola AA, Robinson M, McIsaac RL. Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity. Alimentary Pharmacology & Therapeutics. July 2002, 16 (7): 1317–1326. PMID 12144582. S2CID 34396030. doi:10.1046/j.1365-2036.2002.01291.x .
Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM. Is this the end for ranitidine? NDMA presence continues to confound. Clinical and Translational Science. July 2021, 14 (4): 1197–1200. PMC 8301580 . PMID 33934515. doi:10.1111/cts.12995.
Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, Alghamdi M, Khan AR, Erwin PJ, Sutton AJ, Baddour LM. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLOS ONE //www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620 |PMC=缺少标题 (帮助). 2013, 8 (3). Bibcode:2013PLoSO...856498T. PMC 3587620 . PMID 23469173. doi:10.1371/journal.pone.0056498 . 已忽略未知参数|article-number= (帮助)
Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia. June 2009, 64 (6): 652–657. PMID 19453319. S2CID 7799380. doi:10.1111/j.1365-2044.2008.05861.x .
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Medicine. February 2013, 39 (2): 165–228. PMC 2249616 . PMID 23361625. doi:10.1007/s00134-012-2769-8.
Tang AW. A practical guide to anaphylaxis. American Family Physician. October 2003, 68 (7): 1325–1332 [2017-02-03]. PMID 14567487. （原始内容存档于2017-01-10）.
Force RW, Nahata MC. Effect of histamine H2-receptor antagonists on vitamin B12 absorption. The Annals of Pharmacotherapy. October 1992, 26 (10): 1283–1286. PMID 1358279. S2CID 35308626. doi:10.1177/106002809202601018.
Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. Journal of Clinical Epidemiology. May 2001, 54 (5): 531–534. PMID 11337218. doi:10.1016/S0895-4356(00)00340-1.
Cobelens FG, Leentvaar-Kuijpers A, Kleijnen J, Coutinho RA. Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. Tropical Medicine & International Health. November 1998, 3 (11): 896–903. PMID 9855403.
Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. January 1994, 308 (6922): 176. PMC 2542523 . PMID 7906170. doi:10.1136/bmj.308.6922.176.
Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ. February 1996, 312 (7028): 414–415. PMC 2350063 . PMID 8601113. doi:10.1136/bmj.312.7028.414.
Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. March 1980, 1 (8170): 672–674. PMID 6103090. S2CID 35753958. doi:10.1016/s0140-6736(80)92826-3.
Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB Journal. April 2005, 19 (6): 656–658. PMID 15671152. S2CID 18832411. doi:10.1096/fj.04-3170fje .
Mallow S, Rebuck JA, Osler T, Ahern J, Healey MA, Rogers FB. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?. Current Surgery. 2004, 61 (5): 452–458. PMID 15475094. doi:10.1016/j.cursur.2004.03.014.
Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. May 2006, 117 (5): e817–e820. PMID 16651285. S2CID 23719299. doi:10.1542/peds.2005-1655.
Bangia AV, Kamath N, Mohan V. Ranitidine-induced thrombocytopenia: A rare drug reaction. Indian Journal of Pharmacology //www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128 |PMC=缺少标题 (帮助). February 2011, 43 (1): 76–77. PMC 3062128 . PMID 21455428. doi:10.4103/0253-7613.75676 .
Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, Phelps DL. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. February 2006, 117 (2): e137–e142. PMID 16390920. S2CID 41491264. doi:10.1542/peds.2005-1543.
Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Canani RB. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. January 2012, 129 (1): e40–e45. PMID 22157140. doi:10.1542/peds.2011-0796 .
Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. August 2010, 67 (16): 1344–1350. PMID 20689123. S2CID 12339028. doi:10.2146/ajhp090477.
Wang CH, Chen II, Chen CH, Tseng YT. Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study. International Journal of Environmental Research and Public Health //www.ncbi.nlm.nih.gov/pmc/articles/PMC9566239 |PMC=缺少标题 (帮助). September 2022, 19 (19). PMC 9566239 . PMID 36231768. doi:10.3390/ijerph191912469 . 已忽略未知参数|article-number= (帮助)
Morgan KA, Ahlawat R. Ranitidine. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023 [2023-08-08]. PMID 30422583. （原始内容存档于2023-03-22）.
Roberts CJ. Clinical pharmacokinetics of ranitidine. Clinical Pharmacokinetics. 1984, 9 (3): 211–221. PMID 6329583. S2CID 21561498. doi:10.2165/00003088-198409030-00003.
Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. The New England Journal of Medicine. March 1998, 338 (11): 719–726. PMID 9494148. doi:10.1056/NEJM199803123381104 .

dailymed.nlm.nih.gov

Ranitidine Hydrochloride. DailyMed. August 2020 [2023-08-08]. （原始内容存档于2023-08-10）.
Zantac 150. DailyMed. 2018-04-03 [2021-02-18]. （原始内容存档于2022-07-04）.
Ranitidine hydrochloride capsule. DailyMed. 2018-11-21 [2024-01-07]. （原始内容存档于2025-03-13）.

livertox.nlm.nih.gov

Ranitidine: Hepatotoxicity. U.S. National Institutes of Health (NIH). 2016-06-28 [2016-08-25]. （原始内容存档于2016-08-28）.

nytimes.com (Global: 7^th place; Chinese: 21^st place)

Thomas K. Zantac recall widens as Sanofi pulls its drug over carcinogen fears. The New York Times. 2019-10-18 [2019-10-18]. （原始内容存档于12019-10-18）.
Garcia SE. Zantac pulled from shelves by Walgreens, Rite Aid and CVS over carcinogen fears. The New York Times. 2019-09-30 [2019-10-03]. （原始内容存档于2019-10-03）.

oup.com (Global: 292^nd place; Chinese: 319^th place)

academic.oup.com

Li JJ. Beginning of an Era: The First Blockbuster Drug, Tagamet. academic.oup.com. 2014 [2024 -10-22]. ISBN 978-0-19-973768-0. doi:10.1093/oso/9780199737680.003.0005.

pharmaceutical-journal.com (Global: low place; Chinese: low place)

Connelly D. Return of ranitidine being considered by UK manufacturer. The Pharmaceutical Journal. 2021-10-04 [2021-12-03]. （原始内容存档于2021-12-03）.

regulations.gov (Global: low place; Chinese: low place)

Valisure; (and FDA CDER). Requests FDA to issue a regulation, revise industry guidance, and request a recall and suspend sales of ranitidine from the US market and take such other actions listed in the petition --Valisure FDA Petition, Attachments (and responses). www.regulations.gov. [2024-05-15]. （原始内容存档于2025-05-11）. ranitidine formed millions of nanograms of NDMA [per tablet]

retailpharmacymagazine.com.au (Global: low place; Chinese: low place)

Gloria L. Zantac reinstated in Australian market. Retail Pharmacy. 2024 -10-01 [2025-10-09]. （原始内容存档于2025-04-13）. 请检查|date=中的日期值 (帮助)

semanticscholar.org (Global: 15^th place; Chinese: 141^st place)

api.semanticscholar.org

Gardner JD, Ciociola AA, Robinson M, McIsaac RL. Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity. Alimentary Pharmacology & Therapeutics. July 2002, 16 (7): 1317–1326. PMID 12144582. S2CID 34396030. doi:10.1046/j.1365-2036.2002.01291.x .
Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia. June 2009, 64 (6): 652–657. PMID 19453319. S2CID 7799380. doi:10.1111/j.1365-2044.2008.05861.x .
Force RW, Nahata MC. Effect of histamine H2-receptor antagonists on vitamin B12 absorption. The Annals of Pharmacotherapy. October 1992, 26 (10): 1283–1286. PMID 1358279. S2CID 35308626. doi:10.1177/106002809202601018.
Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. March 1980, 1 (8170): 672–674. PMID 6103090. S2CID 35753958. doi:10.1016/s0140-6736(80)92826-3.
Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB Journal. April 2005, 19 (6): 656–658. PMID 15671152. S2CID 18832411. doi:10.1096/fj.04-3170fje .
Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. May 2006, 117 (5): e817–e820. PMID 16651285. S2CID 23719299. doi:10.1542/peds.2005-1655.
Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, Phelps DL. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. February 2006, 117 (2): e137–e142. PMID 16390920. S2CID 41491264. doi:10.1542/peds.2005-1543.
Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. August 2010, 67 (16): 1344–1350. PMID 20689123. S2CID 12339028. doi:10.2146/ajhp090477.
Roberts CJ. Clinical pharmacokinetics of ranitidine. Clinical Pharmacokinetics. 1984, 9 (3): 211–221. PMID 6329583. S2CID 21561498. doi:10.2165/00003088-198409030-00003.

tga.gov.au (Global: 4,353^rd place; Chinese: 1,620^th place)

Ranitidine. Therapeutic Goods Administration (TGA). 2020-04-02 [2020-07-19]. （原始内容存档于2021-08-29）.
Over-the-counter (OTC) medicine monograph: Ranitidine hydrochloride. Therapeutic Goods Administration (TGA). 2024-10-16 [2025-11-26].
Application (PDF). [2025-10-09].

usatoday.com (Global: 55^th place; Chinese: 147^th place)

Bomey N. Ranitidine warnings: Generic Zantac distribution halted on cancer fear. USA Today. 2019-09-19 [2019-09-20]. （原始内容存档于2019-09-20）.

valisure.com (Global: low place; Chinese: low place)

Earliest NDMA alert. www.valisure.com. [2026-01-20]. （原始内容存档于2025-10-09）. Valisure discovered the link of Zantac and its generics to the carcinogen NDMA during its routine testing of every batch of every medication, and first notified the FDA of its initial findings in June of 2019

web.archive.org (Global: 1^st place; Chinese: 1^st place)

Ranitidine Hydrochloride. DailyMed. August 2020 [2023-08-08]. （原始内容存档于2023-08-10）.
Ranitidine use during pregnancy. Drugs.com. 2019-12-02 [2019-12-13]. （原始内容存档于2019-10-29）.
Acid Reducer (Ranitidine) Tablet: N-nitrosodimethylamine (NDMA) impurity. Health Canada. 2021-12-06 [2024-01-07]. （原始内容存档于2025-03-16）.
Product monograph - PrAcid reducer (PDF). （原始内容 (PDF)存档于2024-01-07）.
Zantac 150. DailyMed. 2018-04-03 [2021-02-18]. （原始内容存档于2022-07-04）.
Ranitidine hydrochloride capsule. DailyMed. 2018-11-21 [2024-01-07]. （原始内容存档于2025-03-13）.
Ranitidine-containing medicinal products. European Medicines Agency (EMA). 2020-04-30 [2020-05-06]. （原始内容存档于2020-05-06）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Ranitidine hydrochloride monograph. The American Society of Health-System Pharmacists. [2015-12-01]. （原始内容存档于2017-09-09）.
Health Canada assessing NDMA in ranitidine. Health Canada. 2019-09-13 [2019-09-26]. （原始内容存档于2019-09-26）.
Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. U.S. Food and Drug Administration (FDA) (新闻稿). 2019-09-13 [2019-09-26]. （原始内容存档于2019-09-26）. 本条目含有公有领域來源内容。
EMA to provide guidance on avoiding nitrosamines in human medicines. European Medicines Agency (EMA) (新闻稿). 2019-09-13 [2019-09-19]. （原始内容存档于2019-12-31）.
FDA updates and press announcements on NDMA in Zantac (ranitidine). U.S. Food and Drug Administration (FDA) (新闻稿). 2019-10-28 [2019-10-28]. （原始内容存档于2019-10-29）. FDA observed the testing method used by a third-party laboratory uses higher temperatures. The higher temperatures generated very high levels of NDMA from ranitidine products because of the test procedure. The FDA published the method for testing angiotensin II receptor blockers (ARBs) for nitrosamine impurities. That method is not suitable for testing ranitidine because heating the sample generates NDMA.
FDA recommends using an LC-HRMS testing protocol to test samples of ranitidine. FDA's LC-HRMS testing method does not use elevated temperatures and has shown the presence of much lower levels of NDMA in ranitidine medicines than reported by the third-party laboratory. International regulators using similar LC-MS testing methods have also shown the presence of low levels of NDMA in ranitidine samples. 本条目含有公有领域來源内容。
Questions and Answers: NDMA impurities in ranitidine (commonly known as Zantac). U.S. Food and Drug Administration (FDA). 2019-10-11 [2019-10-23]. （原始内容存档于2019-10-24）. 本条目含有公有领域來源内容。
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. U.S. Food and Drug Administration (FDA) (新闻稿). 2020-04-01 [2020-04-01]. （原始内容存档于2021-03-28）. 本条目含有公有领域來源内容。
Suspension of ranitidine medicines in the EU. European Medicines Agency (EMA) (新闻稿). 2020-04-30 [2020-06-02]. （原始内容存档于2021-01-05）.
Ranitidine. Therapeutic Goods Administration (TGA). 2020-04-02 [2020-07-19]. （原始内容存档于2021-08-29）.
Gloria L. Zantac reinstated in Australian market. Retail Pharmacy. 2024 -10-01 [2025-10-09]. （原始内容存档于2025-04-13）. 请检查|date=中的日期值 (帮助)
FDA Approves Reformulated Ranitidine Following Comprehensive Safety Review. U.S. Food and Drug Administration (FDA). 2025-11-25 [2025-11-26]. （原始内容存档于2025-12-31）.
Zantac's Maker Kept Quiet About Cancer Risks for 40 Years. Bloomberg. 2023-02-15 [2023-02-20]. （原始内容存档于2023-02-19）.
Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 444. ISBN 978-3-527-60749-5. （原始内容存档于2016 -12-20）.
Reflux Remedies: ranitidine. PharmaSight OTC Health. [2011-11-16]. 原始内容存档于2013-01-12.
Tang AW. A practical guide to anaphylaxis. American Family Physician. October 2003, 68 (7): 1325–1332 [2017-02-03]. PMID 14567487. （原始内容存档于2017-01-10）.
Anaphylaxis: Diagnosis and Management in the Rural Emergency Department (PDF). American Journal of Clinical Medicine. [2017-02-03]. （原始内容存档 (PDF)于2016-08-14）.
Reflux Remedies: ranitidine. PharmaSight OTC Health. PharmaSight.org. [2011-11-19]. 原始内容存档于2017-08-21.
Ranitidine: Hepatotoxicity. U.S. National Institutes of Health (NIH). 2016-06-28 [2016-08-25]. （原始内容存档于2016-08-28）.
Rantac OD 300. Medical Dialogues. [2021-01-19]. （原始内容存档于2022-07-04）.
Ranitidine drug information. Lexicomp. （原始内容存档于2014-04-20）.
Ranitidine - core safety profile (PDF). Bundesinstitut für Arzneimittel und MedizinProdukte. [2019-09-29]. （原始内容存档 (PDF)于2020-11-26）.
Earliest NDMA alert. www.valisure.com. [2026-01-20]. （原始内容存档于2025-10-09）. Valisure discovered the link of Zantac and its generics to the carcinogen NDMA during its routine testing of every batch of every medication, and first notified the FDA of its initial findings in June of 2019
Valisure; (and FDA CDER). Requests FDA to issue a regulation, revise industry guidance, and request a recall and suspend sales of ranitidine from the US market and take such other actions listed in the petition --Valisure FDA Petition, Attachments (and responses). www.regulations.gov. [2024-05-15]. （原始内容存档于2025-05-11）. ranitidine formed millions of nanograms of NDMA [per tablet]
Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines. U.S. Food and Drug Administration (FDA). 2019-09-12 [2020-05-06]. （原始内容存档于2020-05-06）.
Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; additional products being recalled - Recalls and safety alerts. Health Canada. 2019-09-26 [2019-09-26]. （原始内容存档于2019-09-26）.
Bomey N. Ranitidine warnings: Generic Zantac distribution halted on cancer fear. USA Today. 2019-09-19 [2019-09-20]. （原始内容存档于2019-09-20）.
Statement on new testing results, including low levels of impurities in ranitidine drugs. U.S. Food and Drug Administration (FDA) (新闻稿). 2019-11-01 [2019-11-01]. （原始内容存档于2019-11-02）. 本条目含有公有领域來源内容。
Laboratory tests - Ranitidine. U.S. Food and Drug Administration (FDA). 2019-11-01 [2019-11-01]. （原始内容存档于2019-11-02）. 本条目含有公有领域來源内容。
EMA. Suspension of ranitidine medicines in the EU. European Medicines Agency (EMA). 2020-04-30 [2023-03-27]. （原始内容存档于2021-01-05）.
Ranitidine - Drug Usage Statistics. ClinCalc. [2024-03-25]. （原始内容存档于2021-12-07）.
Nitrosamine impurities. European Medicines Agency (EMA). 2020-08-06 [2020-08-06]. （原始内容存档于2020-08-04）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
FDA Provides Guidance to Industry for Detecting and Preventing Nitrosamines in Drugs. U.S. Food and Drug Administration (FDA) (新闻稿). 2020-09-014 [2020-09-01]. （原始内容存档于2020-09-01）. 请检查|date=中的日期值 (帮助)
Control of Nitrosamine Impurities in Human Drugs. U.S. Food and Drug Administration. 2021-02-24 [2024-09-06]. （原始内容存档于2020-09-01）.
Apotex Corp. issues voluntary nationwide recall of Ranitidine tablets 75mg and 150mg (all pack sizes and formats) due to the potential for detection of an amount of unexpected impurity, N-nitrosodimethylamine (NDMA) impurity in the product. U.S. Food and Drug Administration (FDA). 2019-09-26 [2019-09-26]. （原始内容存档于2019-09-26）. 本条目含有公有领域來源内容。
Thomas K. Zantac recall widens as Sanofi pulls its drug over carcinogen fears. The New York Times. 2019-10-18 [2019-10-18]. （原始内容存档于12019-10-18）.
Perrigo Company plc issues voluntary worldwide recall of Ranitidine due to possible presence of impurity, N-nitrosodimethylamine (NDMA) impurity in the product. U.S. Food and Drug Administration (FDA). 2019-10-23 [2019-10-23]. （原始内容存档于2019-10-24）. 本条目含有公有领域來源内容。
Garcia SE. Zantac pulled from shelves by Walgreens, Rite Aid and CVS over carcinogen fears. The New York Times. 2019-09-30 [2019-10-03]. （原始内容存档于2019-10-03）.
Zantac recall – UK recall of Zantac (Ranitidine API), incl. Zantac Injection, Zantac Tablets, Zantac Syrup. GlaxoSmithKline. October 2019 [2020-03-30]. （原始内容存档于2021-12-11）.
MHRA Central Alerting System – Ranitidine: all oral formulations. Supply disruption.. CAS.MHRA.GOV.uk. Medicines and Healthcare products Regulatory Agency (MHRA). 2019-10-15 [2020-03-30]. （原始内容存档于2020-08-13）. All oral formulations of ranitidine are shortly anticipated to be out of stock until further notice. This alert provides healthcare professionals with advice on the management of patients currently taking ranitidine.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020. European Medicines Agency (EMA) (新闻稿). 2020-04-30 [2020-05-06]. （原始内容存档于2020-05-07）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Connelly D. Return of ranitidine being considered by UK manufacturer. The Pharmaceutical Journal. 2021-10-04 [2021-12-03]. （原始内容存档于2021-12-03）.
Morgan KA, Ahlawat R. Ranitidine. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023 [2023-08-08]. PMID 30422583. （原始内容存档于2023-03-22）.
Brunton L, Lazo J, Parker K. Goodman & Gilman's The Pharmacological Basis of Therapeutics 11. McGraw-Hill. August 2005: 972. ISBN 978-0-07-142280-2. （原始内容存档于2016-04-11）.
Zantac. U.S. Food and Drug Administration (FDA). [2019-10-18]. NDA 021698. （原始内容存档于2019-10-30）. 本条目含有公有领域來源内容。
CVS suspends Zantac sales, as recalls widen over carcinogen fears. BioPharma Dive. 2019-09-30 [2019-10-18]. （原始内容存档于2019-10-19）.

雷尼替丁 (Chinese Wikipedia)

aafp.org (Global: 2,559th place; Chinese: 2,134th place)

aapsus.org (Global: low place; Chinese: low place)

adsabs.harvard.edu (Global: 14th place; Chinese: 27th place)

ui.adsabs.harvard.edu

archive.org (Global: 6th place; Chinese: 2nd place)

bfarm.de (Global: low place; Chinese: low place)

biopharmadive.com (Global: low place; Chinese: low place)

bloomberg.com (Global: 118th place; Chinese: 182nd place)

books.google.com (Global: 3rd place; Chinese: 6th place)

canada.ca (Global: 1,114th place; Chinese: 1,607th place)

canada.ca

recalls-rappels.canada.ca

clincalc.com (Global: 5,833rd place; Chinese: 2,124th place)

doi.org (Global: 2nd place; Chinese: 5th place)

drugs.com (Global: 529th place; Chinese: 229th place)

espacenet.com (Global: 950th place; Chinese: 938th place)

worldwide.espacenet.com

europa.eu (Global: 62nd place; Chinese: 150th place)

ema.europa.eu

fda.gov (Global: 470th place; Chinese: 386th place)

fda.gov

accessdata.fda.gov

gskpro.com (Global: low place; Chinese: low place)

hdl.handle.net (Global: 66th place; Chinese: 243rd place)

healthycanadians.gc.ca (Global: low place; Chinese: low place)

hres.ca (Global: low place; Chinese: 7,116th place)

pdf.hres.ca

lexi.com (Global: low place; Chinese: low place)

online.lexi.com

medicaldialogues.in (Global: low place; Chinese: low place)

mhprofessional.com (Global: low place; Chinese: low place)

mhra.gov.uk (Global: low place; Chinese: low place)

cas.mhra.gov.uk

nih.gov (Global: 5th place; Chinese: 3rd place)

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

livertox.nlm.nih.gov

nytimes.com (Global: 7th place; Chinese: 21st place)

oup.com (Global: 292nd place; Chinese: 319th place)

academic.oup.com

pharmaceutical-journal.com (Global: low place; Chinese: low place)

regulations.gov (Global: low place; Chinese: low place)

retailpharmacymagazine.com.au (Global: low place; Chinese: low place)

semanticscholar.org (Global: 15th place; Chinese: 141st place)

api.semanticscholar.org

tga.gov.au (Global: 4,353rd place; Chinese: 1,620th place)

usatoday.com (Global: 55th place; Chinese: 147th place)

valisure.com (Global: low place; Chinese: low place)

web.archive.org (Global: 1st place; Chinese: 1st place)

aafp.org (Global: 2,559^th place; Chinese: 2,134^th place)

adsabs.harvard.edu (Global: 14^th place; Chinese: 27^th place)

archive.org (Global: 6^th place; Chinese: 2^nd place)

bloomberg.com (Global: 118^th place; Chinese: 182^nd place)

books.google.com (Global: 3^rd place; Chinese: 6^th place)

canada.ca (Global: 1,114^th place; Chinese: 1,607^th place)

clincalc.com (Global: 5,833^rd place; Chinese: 2,124^th place)

doi.org (Global: 2^nd place; Chinese: 5^th place)

drugs.com (Global: 529^th place; Chinese: 229^th place)

espacenet.com (Global: 950^th place; Chinese: 938^th place)

europa.eu (Global: 62^nd place; Chinese: 150^th place)

fda.gov (Global: 470^th place; Chinese: 386^th place)

hdl.handle.net (Global: 66^th place; Chinese: 243^rd place)

hres.ca (Global: low place; Chinese: 7,116^th place)

nih.gov (Global: 5^th place; Chinese: 3^rd place)

nytimes.com (Global: 7^th place; Chinese: 21^st place)

oup.com (Global: 292^nd place; Chinese: 319^th place)

semanticscholar.org (Global: 15^th place; Chinese: 141^st place)

tga.gov.au (Global: 4,353^rd place; Chinese: 1,620^th place)

usatoday.com (Global: 55^th place; Chinese: 147^th place)

web.archive.org (Global: 1^st place; Chinese: 1^st place)